Valuation

STAASTAAR Surgical Co

StockNasdaqUnited StatesHealth careEU retail investors: available

−2.6% today · −7.5% over a year

4/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 39% of the instruments we score

Trend: among the weakest. No dividend.

STAAR Surgical Co (STAA) valuation against sector peers: P/B 3.3, free-cash-flow yield 1.4%, P/S 3.8.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricSTAASector medianvs median
P/E2,325.430.9 · n=1597,422% above
P/B3.34.0 · n=30717% below
P/S3.84.1 · n=2999% below
EV/EBIT1,463.725.6 · n=1465,616% above
Free-cash-flow yield1.4%1.4% · n=288near the median
Dividend yield0.00%0.00% · n=362—
Return on equity0.1%−2.1% · n=308—
Return on invested capital0.2%0.6% · n=28266% below
Gross margin73.6%63.3% · n=20516% above
Net debt / EBITDA−21.411.27 · n=1511,792% below

Value factor: 57 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co48.233.0—1.5%0.6%6/10
JNJJohnson & Johnson42.28.3—3.0%1.9%8/10
ABBVAbbVie50.3—27.73.6%2.9%6/10
MRKMerck149.58.2—4.0%2.3%8/10
UNHUnitedHealth22.43.417.16.4%2.3%10/10
TMOThermo Fisher Scientific37.84.935.72.8%0.3%9/10
AMGNAmgen26.817.523.23.8%2.1%8/10
GILDGilead Sciences—16.1—6.6%1.9%5/10
ABTAbbott40.73.832.93.5%2.8%6/10
PFEPfizer41.31.9—7.1%7.4%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 02 Oct 2026 · filed 04 Nov 2026